Katie Jeschke’s Post

Large Molecule Manufacturing: Addressing Challenges with Strategies for Success Large molecule therapeutics have become increasingly prominent, as gene cloning and expression technology made routine production in living cells possible. With innovations in engineering and development technologies responding to the demand for diverse treatment options, these proteins have become more complex. As a result, large molecule manufacturing strategies need to be tailored to ensure high product quality and to meet clinical timelines, whilst also taking into consideration individual customer needs, financial considerations and key IND milestones. The use of protein therapeutics, also known as biologics or large molecule biopharmaceuticals, has played a central role in advancing the industry in pursuing unmet patient medical needs. https://lnkd.in/gADMGQkb #aspenalert #biotech #bioprocess

❗📚💡 Protein isoform-centric therapeutics: expanding targets and increasing specificity

In the dynamic world of #biopharmaceuticals, the production of monoclonal antibodies (#mAbs) and recombinant proteins using mammalian cells has not just been a trend but a transformative leap forward. Over the last decade, this advancement has propelled a significant influx of #biotherapeutic proteins into the market, revolutionizing patient care and treatment options. As the industry continues to grow, the pressure to reduce development costs and accelerate time-to-market for these life-saving treatments has never been higher. That‘s where our eBook, “Optimize your high-value cell lines,“ comes in! A comprehensive eBook designed to guide you through the complexities of #celllinedevelopment, this essential read offers an in-depth overview of the cell line development workflow, highlighting innovative high-throughput solutions that streamline the process, making it easier and faster to identify and select high-producing mammalian cell lines. Download now and pave the way for faster, more efficient delivery of next-generation biotherapeutics. 👇 https://lnkd.in/gZUCnQ2h Clone Screening | Molecular Devices

IF1 Protein Controls Aging Rate https://lnkd.in/eJuRvRDH { #longevity #aging #ageing #drug #cancer #cancerresearch #science #biotech #pharma #pharmaceutical #business #cosmetics #vc #venturecapital #biology #biochemistry #chemistry #medicine #investment #startups #technology #oncology }

In the dynamic world of #biopharmaceuticals, the production of monoclonal antibodies (#mAbs) and recombinant proteins using mammalian cells has not just been a trend but a transformative leap forward. Over the last decade, this advancement has propelled a significant influx of #biotherapeutic proteins into the market, revolutionizing patient care and treatment options. As the industry continues to grow, the pressure to reduce development costs and accelerate time-to-market for these life-saving treatments has never been higher. That‘s where our eBook, “Optimize your high-value cell lines,“ comes in! A comprehensive eBook designed to guide you through the complexities of #celllinedevelopment, this essential read offers an in-depth overview of the cell line development workflow, highlighting innovative high-throughput solutions that streamline the process, making it easier and faster to identify and select high-producing mammalian cell lines. Download now and pave the way for faster, more efficient delivery of next-generation biotherapeutics. 👇 https://lnkd.in/gZUCnQ2h Clone Screening | Molecular Devices

Excited to share our recent article on "Drug Product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-based Genomic Medicines"! While AAV-based therapies hold immense promise, the successful translation of these therapies from bench to bedside requires meticulous attention to the process/formulation and manufacturing processes. The field, however, is still in the early stages of gaining experience with AAV stability, analytics, and manufacturing processes. Here is an effort to comprehensively summarize the current state for AAV formulation and DP mfg. processes, the screening & stabilizing strategies as well as the learnings from protein biologics to accelerate development of this promise to patients. Read the full article here: https://lnkd.in/gCuXcmVF Congratulations!! to the authors for this excellent contribution to the field.

Thoughts on this? >> ProBio Expands Plasmid DNA and Viral Vector Production in New Jersey to Accelerate Delivery of Life-Changing Cell ... - PR Newswire >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #pharma #healthcare #biotech

Transform your break time into a learning experience! 🧪 We're hosting a range of webinars aimed at exploring the use of light scattering techniques in drug development. Whether you're working with CGT, protein therapeutics, or vaccines, we have something for you. From enhancing the analysis of macromolecules to expediting the development of Antibody Drug Conjugates, our sessions are designed to take your knowledge to the next level. Join us in advancing together in this scientific journey. Register now! #Waters #Wyatt #DrugDevelopment #LightScattering 💡Session 1 | Wed., July 3 | 10:00-11:00 (BST), 11:00-12:00 (CEST) Light Scattering Solutions for Multi-Attribute Quantification of mRNA-lipid Nanoparticle Therapeutics 💡Session 2 | Wed., July 17 | 10:00-11:00 (BST), 11:00-12:00 (CEST) Smaller Particle and Low Adsorption Columns for Fast and Efficient Characterization of AAV through SEC-MALS 💡Session 3 | Wed., July 31 | 10:00-11:00 (BST), 11:00-12:00 (CEST) Exploring Enhanced Macromolecular and Nanoparticle Analysis through the Integration of DLS/ELS/SLS with the ZetaStar Instrument 💡Session 4 | Wed., August 14 | 10:00-11:00 (BST), 11:00-12:00 (CEST) In-Line and On-Line Monitoring of CQAs for Biologics, Vaccines and Gene Vectors 💡Session 5 | Wed., Sept 4 | 10:00-11:00 (BST), 11:00-12:00 (CEST) Learning Advanced Analytical Technologies to Expedite the Development of Antibody Drug Conjugates 💡Session 6 | Wed., September 18 | 10:00-11:00 (BST), 11:00-12:00 (CEST) Quality Control of Purified Proteins to Improve Research Data Reproducibility: Improving the Time-Efficiency and Quality of Your Results Link to register in the comments 👇

In this interesting paper, the authors used a synthetic biology tool to better exploit the widely used GS selection marker (split intein-mediated protein ligation of GS; SiMPl-GS). The aim was to investigate if this approach could be beneficial in cell line development - especially when trying to express recombinant proteins such as multi specific antibodies. Pools expressing mAbs, created using this system, were observed to be enriched for high producers - and the system was demonstrated to be a promising approach for expressing multi specific antibodies. #celllinedevelopment #CHO #GS #syntheticbiology #selectionmarker #multispecificantibody #bispecificantibody #biotherapeutics #biopharmaceuticals https://lnkd.in/eJuyHYtf

#Yeast antibody = #CHO antibody?...Monoclonal antibodies--an essential class of #biopharmaceuticals--are made in mammalian cells today. #Alternativehosts could expand #accessibility and improve #resiliency of their production. Congratulations to Elvin Yang, Neil Dalvie and colleagues (including Eric Lee Mark Tie from Biogen and Mary Kate Tracey and Kerry Love 🌻) on their research that shows comparable quality of a minimally modified antibody for both #yeast and #CHO, potentially accelerating #rapidresponse and #translationaldevelopment. https://lnkd.in/e4KQ2NZ8